BR112021020279A2 - Derivados de piridopirimidinas como inibidores de p2x3 - Google Patents

Derivados de piridopirimidinas como inibidores de p2x3

Info

Publication number
BR112021020279A2
BR112021020279A2 BR112021020279A BR112021020279A BR112021020279A2 BR 112021020279 A2 BR112021020279 A2 BR 112021020279A2 BR 112021020279 A BR112021020279 A BR 112021020279A BR 112021020279 A BR112021020279 A BR 112021020279A BR 112021020279 A2 BR112021020279 A2 BR 112021020279A2
Authority
BR
Brazil
Prior art keywords
compounds
inhibitors
pyridopyrimidines
relates
derivatives
Prior art date
Application number
BR112021020279A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Baker-Glenn
Claudio Fiorelli
VAN DE POËL Hervè
Matteo Biagetti
Paolo Bruno
Roberta Lanaro
David Penrose Stephen
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of BR112021020279A2 publication Critical patent/BR112021020279A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021020279A 2019-05-31 2020-05-28 Derivados de piridopirimidinas como inibidores de p2x3 BR112021020279A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19177610 2019-05-31
EP19201165 2019-10-02
PCT/EP2020/064915 WO2020239953A1 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as p2x3 inhibitors

Publications (1)

Publication Number Publication Date
BR112021020279A2 true BR112021020279A2 (pt) 2021-12-14

Family

ID=70857198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020279A BR112021020279A2 (pt) 2019-05-31 2020-05-28 Derivados de piridopirimidinas como inibidores de p2x3

Country Status (11)

Country Link
US (1) US12606562B2 (https=)
EP (1) EP3976609A1 (https=)
JP (1) JP7797204B2 (https=)
KR (1) KR102923602B1 (https=)
CN (1) CN114222741B (https=)
AU (1) AU2020281924B2 (https=)
BR (1) BR112021020279A2 (https=)
CA (1) CA3136024A1 (https=)
MA (1) MA56020A (https=)
MX (1) MX2021014116A (https=)
WO (1) WO2020239953A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
AR132737A1 (es) 2023-05-22 2025-07-23 Chiesi Farm Spa Proceso e intermedios para la preparación de un inhibidor p2x3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
CN101300012B (zh) * 2005-09-01 2011-09-14 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用
MX2008014689A (es) 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
EP2038264B1 (en) 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PT2139334E (pt) 2007-04-17 2013-10-02 Evotec Ag Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
BRPI0919488A2 (pt) 2008-09-30 2015-12-01 Astrazeneca Ab composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
KR101685862B1 (ko) 2012-12-27 2016-12-20 에프. 호프만-라 로슈 아게 Comt 억제제
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
JPWO2016084922A1 (ja) 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
DK3355889T3 (da) 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste
JP6882289B2 (ja) * 2015-11-25 2021-06-02 コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ 二環式ｂｅｔブロモドメイン阻害剤及びその使用
CN106565684B (zh) 2016-03-18 2019-06-18 南方医科大学 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用
CA3029457A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
RS63661B1 (sr) * 2018-07-25 2022-11-30 Faes Farma Sa Piridopirimidini kao inhibitori histaminskog h4-receptora
CN109721554A (zh) 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors

Also Published As

Publication number Publication date
JP2022534434A (ja) 2022-07-29
JP7797204B2 (ja) 2026-01-13
WO2020239953A1 (en) 2020-12-03
US20230212169A9 (en) 2023-07-06
US20220235060A1 (en) 2022-07-28
CN114222741A (zh) 2022-03-22
KR20220016074A (ko) 2022-02-08
US12606562B2 (en) 2026-04-21
MA56020A (fr) 2022-04-06
AU2020281924A1 (en) 2021-12-16
CA3136024A1 (en) 2020-12-03
AU2020281924B2 (en) 2026-04-16
MX2021014116A (es) 2021-12-10
EP3976609A1 (en) 2022-04-06
KR102923602B1 (ko) 2026-02-06
CN114222741B (zh) 2025-12-30

Similar Documents

Publication Publication Date Title
BR112021021738A2 (pt) Derivados de amino quinazolina como inibidores de p2x3
BR112021020279A2 (pt) Derivados de piridopirimidinas como inibidores de p2x3
SA519402319B1 (ar) Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
UY35963A (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
CL2020002939A1 (es) Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
BR112023004612A2 (pt) Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-acetamida como inibidores de receptor i de fator-beta de crescimento transformador/alk5
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
MX387125B (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
MX2021000270A (es) Derivados de la tirosina amida como inhibidores de la rho- cinasa.
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
BRPI0511424A (pt) composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
BRPI0608074A2 (pt) derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
MX2023005803A (es) Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3).
BR112019001217A2 (pt) peptídeos cíclicos como antagonistas de receptor de c5a
BR112022021391A2 (pt) N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4
BR112017004163A2 (pt) método de tratamento e composições com um inibidor de quinase pi3k delta e gamma duplo e um corticostoide
MX2023005865A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2021015553A (es) Inhibidores de arginasa novedosos.
EA202193300A1 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]